Compare GTEC & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTEC | LNAI |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | 340 | 29 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 11.7M |
| IPO Year | N/A | N/A |
| Metric | GTEC | LNAI |
|---|---|---|
| Price | $0.53 | $0.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 101.6K | ★ 3.3M |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.15 |
| 52 Week High | $2.26 | $1.66 |
| Indicator | GTEC | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 34.30 | 37.06 |
| Support Level | $0.47 | $0.15 |
| Resistance Level | $0.80 | $0.41 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 34.79 | 1.72 |
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.